First Citizens Bank & Trust Co. acquired a new stake in shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 170,502 shares of the company’s stock, valued at approximately $11,083,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of America Corp DE boosted its position in shares of SPDR S&P Pharmaceuticals ETF by 128.0% during the 1st quarter. Bank of America Corp DE now owns 811,939 shares of the company’s stock worth $43,918,000 after purchasing an additional 455,802 shares in the last quarter. Private Advisor Group LLC acquired a new stake in shares of SPDR S&P Pharmaceuticals ETF in the 1st quarter valued at about $3,017,000. Integrated Wealth Concepts LLC bought a new stake in SPDR S&P Pharmaceuticals ETF in the 2nd quarter valued at about $3,350,000. Avior Wealth Management LLC bought a new stake in SPDR S&P Pharmaceuticals ETF in the 3rd quarter valued at about $1,172,000. Finally, SummitTX Capital L.P. acquired a new position in SPDR S&P Pharmaceuticals ETF during the 1st quarter worth approximately $843,000.
SPDR S&P Pharmaceuticals ETF Stock Performance
XPH stock opened at $62.10 on Wednesday. The company has a market cap of $450.23 million, a P/E ratio of 14.28 and a beta of 0.61. SPDR S&P Pharmaceuticals ETF has a fifty-two week low of $46.90 and a fifty-two week high of $74.35. The stock’s 50 day simple moving average is $68.53 and its 200 day simple moving average is $63.59.
About SPDR S&P Pharmaceuticals ETF
SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Read More
- Five stocks we like better than SPDR S&P Pharmaceuticals ETF
- Tax Credit Turmoil: Why Enphase and SolarEdge Face a Tough Road
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
Want to see what other hedge funds are holding XPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Free Report).
Receive News & Ratings for SPDR S&P Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
